Holen Sie sich die Stockscreener-App
20.81
1.57%
-0.54
Schlusskurs vom Vortag:
$21.35
Offen:
$21.24
24-Stunden-Volumen:
156.47K
Relative Volume:
0.09
Marktkapitalisierung:
$2.57B
Einnahmen:
$247.00M
Nettoeinkommen (Verlust:
$-249.00M
KGV:
-6.7346
EPS:
-3.09
Netto-Cashflow:
$-267.00M
1W Leistung:
-9.77%
1M Leistung:
-16.17%
6M Leistung:
+125.24%
1J Leistung:
+40.85%
1-Tages-Spanne:
$20.76
$21.30
1-Wochen-Bereich:
$20.59
$23.39
52-Wochen-Spanne:
$6.50
$26.40
Arcus Biosciences Inc Stock (RCUS) Company Profile
Firmenname
Arcus Biosciences Inc
Sektor
Branche
Telefon
(510) 694-6200
Adresse
3928 POINT EDEN WAY, HAYWARD, CA
Vergleichen Sie RCUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
20.76 | 2.64B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.19 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
810.84 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.64 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
815.91 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.19 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-10-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2020-04-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-09-27 | Eingeleitet | Mizuho | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2018-10-09 | Eingeleitet | Wedbush | Outperform |
| 2018-04-09 | Eingeleitet | Citigroup | Buy |
| 2018-04-09 | Eingeleitet | Goldman | Neutral |
| 2018-04-09 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Arcus Biosciences Inc Aktie (RCUS) Neueste Nachrichten
Is Arcus Biosciences Inc. stock a buy for dividend growthWeekly Market Outlook & Smart Allocation Stock Tips - ulpravda.ru
Growth Review: Is Arcus Biosciences Inc. stock a buy for dividend growth2025 Trading Volume Trends & Fast Moving Stock Trade Plans - ulpravda.ru
Arcus Biosciences (RCUS) Downgraded by Morgan Stanley Amid Recen - GuruFocus
Can Arcus Biosciences Inc. stock double in next 5 yearsMarket Performance Recap & AI Enhanced Trade Execution Alerts - ulpravda.ru
Will Arcus Biosciences Inc. stock maintain growth storyJuly 2025 Earnings & Accurate Buy Signal Alerts - ulpravda.ru
Arcus stock downgraded at Morgan Stanley (RCUS:NYSE) - Seeking Alpha
Morgan Stanley Downgrades Arcus Biosciences (RCUS), Adjusts Pric - GuruFocus
Morgan Stanley downgrades Arcus Biosciences stock on balanced risk/reward - Investing.com Canada
Arcus Biosciences (RCUS) Sets Ambitious 2026 Agenda for Casdatif - GuruFocus
Biotech outlines 2026 plans for kidney cancer and atopic dermatitis - Stock Titan
Arcus Biosciences (RCUS) Shares Fall by Over 9% - GuruFocus
Arcus Biosciences (NYSE:RCUS) Trading Down 7.8% Following Insider Selling - MarketBeat
Portfolio Shifts: Is Arcus Biosciences Inc stock a buy for dividend growthLong Setup & AI Powered Buy and Sell Recommendations - moha.gov.vn
Insider Sell: Goeltz II Robert C. Sells Shares of Arcus Bioscien - GuruFocus
Insider Selling: Arcus Biosciences (NYSE:RCUS) CFO Sells 6,552 Shares of Stock - MarketBeat
The Technical Signals Behind (RCUS) That Institutions Follow - Stock Traders Daily
Arcus Biosciences (NYSE:RCUS) Trading Up 2.8%Should You Buy? - MarketBeat
Certain Common Stock of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 30-DEC-2025. - marketscreener.com
Certain Stock Optios of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 30-DEC-2025. - marketscreener.com
Certain Restricted Stock Units of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 30-DEC-2025. - MarketScreener
Is Arcus Biosciences Inc a good long term investmentDebt-to-Equity Ratio Analysis & AI-Based Predictions Available Free - earlytimes.in
Arcus Biosciences Earnings Notes - Trefis
Understanding Momentum Shifts in (RCUS) - news.stocktradersdaily.com
Can Arcus Biosciences Inc. stock deliver consistent earnings growthQuarterly Investment Review & Comprehensive Market Scan Reports - Улправда
Have Insiders Sold Arcus Biosciences Shares Recently? - simplywall.st
Squarepoint Ops LLC Boosts Stake in Arcus Biosciences, Inc. $RCUS - MarketBeat
Can Arcus Biosciences Inc. stock deliver sustainable ROEMarket Sentiment Report & Technical Confirmation Trade Alerts - Улправда
How higher bond yields impact Arcus Biosciences Inc. stockJuly 2025 Breakouts & Safe Entry Trade Signal Reports - ulpravda.ru
Is Arcus Biosciences Inc. stock attractive after correctionEarnings Growth Summary & Weekly Stock Performance Updates - Bölüm Sonu Canavarı
Market Outlook: Can Arcus Biosciences Inc. stock maintain operating marginsQuarterly Market Summary & Daily Entry Point Trade Alerts - DonanımHaber
Arcus Biosciences (NYSE:RCUS) Insider Richard Markus Sells 4,494 Shares - MarketBeat
Insider Selling: Arcus Biosciences (NYSE:RCUS) CAO Sells 4,343 Shares of Stock - MarketBeat
Carolyn Tang Sells 7,658 Shares of Arcus Biosciences (NYSE:RCUS) Stock - MarketBeat
Arcus Biosciences (NYSE:RCUS) President Sells $245,603.00 in Stock - MarketBeat
Robert Goeltz II Sells 6,702 Shares of Arcus Biosciences (NYSE:RCUS) Stock - MarketBeat
Arcus Biosciences (NYSE:RCUS) CEO Sells $633,360.36 in Stock - MarketBeat
Arcus Biosciences (NYSE:RCUS) General Counsel Sells $150,909.60 in Stock - MarketBeat
Arcus Biosciences amends loan agreement, extends maturity and updates terms - Investing.com Nigeria
Arcus Biosciences Insider Sold Shares Worth $466,870, According to a Recent SEC Filing - marketscreener.com
Arcus Biosciences Insider Sold Shares Worth $278,739, According to a Recent SEC Filing - marketscreener.com
Arcus Biosciences Insider Sold Shares Worth $318,496, According to a Recent SEC Filing - marketscreener.com
Arcus Biosciences Executives Sell Shares to Cover Tax Obligations - TradingView — Track All Markets
Officer Azoy Sells 4,343 ($96.6K) Of Arcus Biosciences Inc [RCUS] - TradingView — Track All Markets
[Form 4] Arcus Biosciences, Inc. Insider Trading Activity - Stock Titan
Arcus Biosciences Amends Loan Facility, Extends Maturity Terms - TipRanks
Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference - marketscreener.com
Cancer-focused Arcus Biosciences to present at major health conference - Stock Titan
February 2026 Options Now Available For Arcus Biosciences (RCUS) - Nasdaq
This growth stock with 137% upside faces new challenge: Buy, hold or sell? - MSN
Arcus Biosciences: Casdatifan Takes Center Stage After STAR-221 (NYSE:RCUS) - Seeking Alpha
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Finanzdaten der Arcus Biosciences Inc-Aktie (RCUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):